CWA Asset Management Group LLC Has $821,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

CWA Asset Management Group LLC lowered its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 21.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,291 shares of the biotechnology company’s stock after selling 4,509 shares during the quarter. CWA Asset Management Group LLC’s holdings in Corcept Therapeutics were worth $821,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CORT. Natixis Advisors LLC raised its stake in Corcept Therapeutics by 16.0% in the second quarter. Natixis Advisors LLC now owns 20,660 shares of the biotechnology company’s stock valued at $671,000 after buying an additional 2,854 shares during the period. Arizona State Retirement System increased its holdings in shares of Corcept Therapeutics by 8.3% in the second quarter. Arizona State Retirement System now owns 26,081 shares of the biotechnology company’s stock valued at $847,000 after purchasing an additional 2,001 shares during the last quarter. Savant Capital LLC raised its position in shares of Corcept Therapeutics by 44.0% in the second quarter. Savant Capital LLC now owns 18,325 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 5,602 shares during the period. Quest Partners LLC lifted its stake in shares of Corcept Therapeutics by 23.2% during the 2nd quarter. Quest Partners LLC now owns 5,266 shares of the biotechnology company’s stock worth $171,000 after buying an additional 992 shares during the last quarter. Finally, Texas Permanent School Fund Corp boosted its holdings in shares of Corcept Therapeutics by 3.6% during the 2nd quarter. Texas Permanent School Fund Corp now owns 82,287 shares of the biotechnology company’s stock worth $2,674,000 after buying an additional 2,897 shares during the period. Institutional investors own 93.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Truist Financial increased their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a report on Monday, September 30th. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Finally, Piper Sandler raised their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Stock Down 0.8 %

Shares of NASDAQ CORT opened at $51.25 on Wednesday. Corcept Therapeutics Incorporated has a 52 week low of $20.84 and a 52 week high of $62.22. The stock’s fifty day moving average is $54.69 and its 200 day moving average is $43.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock has a market capitalization of $5.37 billion, a P/E ratio of 40.67 and a beta of 0.56.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. The company had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 EPS. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 1.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider William Guyer sold 3,394 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $48.97, for a total transaction of $166,204.18. Following the sale, the insider now directly owns 5,796 shares of the company’s stock, valued at approximately $283,830.12. The trade was a 36.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares of the company’s stock, valued at $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,811 shares of company stock valued at $1,840,080. 20.50% of the stock is currently owned by corporate insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.